This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Dendreon: Provenge Sales, Guidance Fall Short

Stocks in this article: DNDN

SEATTLE ( TheStreet) -- Dendreon (DNDN) reported third quarter Provenge sales of $20.2 million and forecast 2011 sales that are short of Wall Street's consensus estimates.

Provenge, a prostate cancer immunotherapy, was launched in May but sales are constrained because Dendreon is operating a single manufacturing plant at less than full capacity and still building two others. Dendreon has told investors that about 2,000 patients would be treated with Provenge in the first 12 months of the launch and that manufacturing would reach full capacity in the middle of 2011.

Dendreon said Wednesday it expects 2011 revenue in the range of $350 million to $400 million, with half of that to be generated in the fourth quarter.

The new guidance is below the Street's current consensus revenue estimate of $402 million, which suggests either analysts are over-reaching or Dendreon is being conservative.

The $20.2 million in Provenge sales for the third quarter fell about $4 million short of expectations, although monthly sales grew each month during the quarter and in October, Provenge sales were $9.5 million, the company said.

Doctors have written about 1,000 prescriptions for Provenge since the drug was launched, the company added. That's double the number of Provenge prescriptions reported by Dendreon on its second-quarter conference call.

"We’re pleased with the progress we have made in the first six months of the launch of Provenge," said Dendreon CEO Mitch Gold, in a statement.

For the September quarter, Dendreon reported a net loss of $79.3 million, or 56 cents a share, which includes a charge for a litigation settlement equal to 9 cents a share. In the prior September quarter, Dendreon lost $45.6 million, or 40 cents a share.

Dendreon shares closed Wednesday at $38.59 but were down 5% to $37 in the after-hours session.

--Written by Adam Feuerstein in Boston.



>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.

Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,827.75 +12.81 0.07%
S&P 500 2,072.83 +5.80 0.28%
NASDAQ 4,787.3170 +29.0650 0.61%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs